Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbbVie
(NY:
ABBV
)
159.62
-7.67 (-4.58%)
Official Closing Price
Updated: 4:10 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
53
54
Next >
Healthcare Gems: 3 Essential Long-Term Stock Picks
December 07, 2023
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks.
Via
InvestorPlace
AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals
December 07, 2023
Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the...
Via
Benzinga
Why Methode Electronics Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
December 07, 2023
Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings.
Via
Benzinga
Is AbbVie Stock a Buy Now?
December 07, 2023
AbbVie's business could soon become more diversified.
Via
The Motley Fool
Decoding AbbVie's Options Activity: What's the Big Picture?
December 05, 2023
Via
Benzinga
Analyst Ratings for AbbVie
December 01, 2023
Via
Benzinga
Why Cerevel Therapeutics Stock Is Higher
December 07, 2023
Cerevel Therapeutics Holdings, Inc.
Via
Benzinga
Verint Reports Strong Earnings, Joins Semtech, Alphabet And Other Big Stocks Moving Higher On Thursday
December 07, 2023
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining more than 100 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Cerevel Therapeutics (CERE) Stock Up 12% Today?
December 07, 2023
Cerevel Therapeutics stock is climbing higher as CERE investors react to an $8.7 billion acquisition deal with AbbVie.
Via
InvestorPlace
Why Cerevel Therapeutics Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
December 07, 2023
Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) jumped in pre-market trading after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity value of approximately...
Via
Benzinga
Health Care Company AbbVie Announces Acquisition of Immunogen
November 30, 2023
Via
Benzinga
AbbVie Should Consider a Dividend Cut -- Here's Why
November 30, 2023
Dividend Kings with above-average yields have been badly underperforming the broader markets.
Via
The Motley Fool
Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?
December 07, 2023
There's no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has a clear edge.
Via
The Motley Fool
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
December 07, 2023
These particular players look cheap right now.
Via
The Motley Fool
Why Cerevel Therapeutics Holdings Is Moving After-Hours
December 06, 2023
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading higher in Wednesday's after-hours session after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity...
Via
Benzinga
7 High-Dividend Stocks to Buy for a Lifetime of Passive Income
December 06, 2023
These high-dividend stocks are among the biggest beneficiaries of current mega trends, and investors can leverage them for big gains.
Via
InvestorPlace
Small Cap, Big Potential: 3 Russell 2000 Stocks to Watch
December 06, 2023
The Russell 2000 index comprises small-cap companies, exposing investors to small organizations. Consider buying these Russell 2000 stocks.
Via
InvestorPlace
3 Stocks at the Forefront of Personalized Medicine Trend
December 05, 2023
Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly
Via
InvestorPlace
ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note
December 04, 2023
AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $
Via
Benzinga
AbbVie's Big Buy Of ImmunoGen Opens Doors For Potential Investment Gains
December 04, 2023
AbbVie's $10.1 billion acquisition of ImmunoGen, with its promising ovarian cancer drug, Elahere, signals a strategic move in the competitive cancer drug market. Investors anticipate market reactions,...
Via
Talk Markets
2 Dividend Stocks to Buy and Hold Forever
December 02, 2023
These stocks offer much more than reliable dividends.
Via
The Motley Fool
5 S&P 500 Stocks That Pay a Generous Dividend
December 02, 2023
Investors are pocketing dividend yields between 4% and 9% with these stocks.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
December 01, 2023
Software earnings were strong, while the Fed is shifting toward rate cuts.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
November 30, 2023
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion.
Via
Talk Markets
Why Abbvie Stock Popped Today
November 30, 2023
The company announces a major deal worth over $10 billion.
Via
The Motley Fool
ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal
November 30, 2023
AbbVie Inc (NYSE: ABBV) has agreed to acquire ImmunoGen Inc (NASDAQ: IMGN) and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC)...
Via
Benzinga
Why Is ImmunoGen (IMGN) Stock Up 81% Today?
November 30, 2023
ImmunoGen stock is taking off on news that AbbVie is acquiring all outstanding shares of IMGN in a $10.1 billion acquisition deal.
Via
InvestorPlace
AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal
November 30, 2023
IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion, offering a rich premium for the maker of cancer drug Elahere.
Via
Investor's Business Daily
Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today’s Economy
November 29, 2023
These are the best blue-chip stocks for investors to consider among a group of already strong equities available in the market.
Via
InvestorPlace
AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients
November 29, 2023
AbbVie Inc (NYSE: ABBV) announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
53
54
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.